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OBJECTIVES: To assess, from a societal perspective, 
the cost-effectiveness of use of ramipril (Altace®) after
invasive revascularization, based on the Angiotensin-
converting Enzyme Inhibition Post Revascularization
Study (APRES), which found that ramipril was associated
with signiﬁcantly reduced risk of cardiac mortality and of
non-fatal events. 
METHODS: Probabilities of acute myocardial infarction
(AMI), congestive heart failure (CHF), angina pectoris
and cardiac mortality associated with ramipril or placebo
from APRES, a randomized, double-blind, placebo-
controlled study of 159 patients who had undergone
revascularization were applied to a decision-analytic
model. Reduction in risk of non-fatal events was used to
model expected costs and reduction in risk of cardiac
mortality was used to deﬁne effectiveness. Unit costs were
based on hospitalization charges from the 1997 Health-
care Cost and Utilization Project (HCUP-3), adjusted 
by the Medicare cost-to-charge ratio, as well as costs
obtained from published literature. Drug costs were 
based on published average wholesale prices (AWP) from
the 1997 Red Book. All costs were discounted at 3% per
year.
RESULTS: Based on average daily AWP of $0.94,
ramipril was associated with a discounted incremental
cost of $934 per patient over 33 months of treatment and,
after accounting for cost offsets due to reduced risk of
clinical events, a net expected incremental cost per patient
of $327. Given a 7.6% absolute risk reduction in cardiac
mortality (8.9% less 1.3%, p < 0.05), ramipril was asso-
ciated with an incremental expected cost of $4,300 per
death averted and, correspondingly, $371 per life year
saved, based on additional life expectancy in this patient
population. Sensitivity analysis indicated that these esti-
mates ranged from a total cost offset (minus $61 per life
year saved) in the best scenario to $861 per life year saved
in the worst scenario.
CONCLUSIONS: Ramipril is expected to be a cost-
effective addition to medical management of patients
undergoing revascularization.
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Overweight and obesity are seen to be major risk factors
for costly chronic diseases and can worsen other chronic
conditions, leading to important health care resources
absorption. There is evidence that health care resources
use is associated with the severity of obesity expressed as
body mass index (BMI).
OBJECTIVES: To examine direct and indirect costs per
overweight and obese subject and to investigate the asso-
ciation between BMI and the costs of caring for over-
weight and obese subjects.
METHODS: The ﬁrst 10 overweight and obese subjects
attending 52 medical ofﬁces in Italy were enrolled.
Medical and economic information was retrospectively
collected using an electronic questionnaire. The societal
perspective was adopted. Costs considered were direct
(visits, diagnostics, drugs, other therapies, hospitalisa-
tions) and indirect (working activity reduction or
abandon) and refer to a 6-month period. The association
of costs with BMI was explored using parametric and non
parametric tests as appropriate. All costs are in Euro year
2001 (1 Euro = 0.9 US$).
RESULTS: The mean age of the 367 subjects enrolled was
43.18 (±12.9) and the mean BMI 35.34 (±6.72). 73.6%
of the subjects were females, and 77.7% obese (BMI >
30). The mean 6-months health-care cost estimated was
855 Euro per subject. Hospitalisation was the health-care
cost driver (64% of the total), followed by drugs (7%),
visits and diagnostics (6% each). 16% percent of the
sample reduced working activity by 35% on average. The
cost of care for an overweight subject was signiﬁcantly
lower compared to an obese (685 vs. 917 Euro, P =
0.011). BMI was associated with direct costs (P = 0.004)
and with work abandon or reduction (p = 0.001). 
CONCLUSIONS: The present study gives the opportu-
nity to understand how health care expenditure vary
across a wide range of BMI values in Italy and this could
have important implications for targeting preventive and
weight reduction interventions.
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Studies show that aspirin is very effective as secondary
prevention of cardiovascular events, however its use for
primary prevention of cardiovascular disease (CVD) is
questionable. There are clinical trials performed to study
its effectiveness for primary prevention, however cost-
effectiveness studies have not been done to see the trade-
off between decreased CVD and increased adverse events.
OBJECTIVES: Primarily, this paper seeks to calculate 
the incremental cost-effectiveness ratios (ICERs) of using
aspirin in males and females aged 40–80 with no prior
history of CVD. Secondarily, to calculate the ICERs of
HMG-CoA Reductase Inhibitors compared to aspirin. 
METHODS: The cost-effectiveness ratios were calculated
for a hypothetical cohort of patients using a decision 
analytic spreadsheet model with a societal perspective in
2001 U.S. Dollars. Measurements of costs, effectiveness,
utilities, and rates of events were obtained from literature.
A series of one-way sensitivity analyses were performed 
to test the robustness of the model. For the secondary
objective, the incremental costs and incremental CVD risk
reduction obtained from using HMG-CoA Reductase
Inhibitors instead of aspirin is applied to the model to
